Abstract:Objective: Antipsychotics, such as aripiprazole and risperidone, are often used to treat individuals with schizophrenia. The efficacy as well as safety of aripiprazole in Western populations has been described. The objective of this study is to investigate the efficacy, safety, and tolerability of aripiprazole and risperidone in Chinese Han schizophrenia subjects in mainland China. Method: The 6-week, double-blind, randomized, parallel study was conducted in 5 medical centers in mainland China from November 2007 to March 2011. A total of 279 subjects with a primary DSM-IV diagnosis of schizophrenia were randomly assigned (with a randomization ratio of 1: 1) to aripiprazole (n = 139) or risperidone (n = 140). Efficacy measurements included the Positive and Negative Syndrome Scale (PANSS) total, positive, negative and general psychopathology subscale scores, and Clinical Global Impressions-Severity of Illness (CGI-S), and Improvement scale scores. Extrapyramidal symptoms (EPS), weight gain, serum prolactin level, QTc interval, and self-reported adverse events were also assessed as measures of safety and tolerability. Results: Both the aripiprazole and risperidone groups showed statistically significant improvement of PANSS total, positive, negative, general psychopathology subscale scores, and CGI-S scores from baseline to the endpoint (all p < 0.01). Significant improvement was noted in the first week for both treatment groups. There were no significant differences in efficacy measurements between the two treatment groups. Mean change of PANSS total scores from baseline to the endpoint was -26.8 +/- 18.1 for aripiprazole and -30.0 +/- 17.7 for risperidone, (p = 0.1475). The responder rate was 71% (n = 99) and 76% (n = 107) for aripiprazole and risperidone, respectively, (p = 0.323). The incidences of EPS were similar in the aripiprazole (25%, n = 35) and risperidone groups (24%, n = 34), respectively (p = 0.757). No clinically meaningful effects on QTc interval, QRS duration, or PR interval were observed in either treatment groups. However, the incidence of clinically significant weight gain (p = 0.0118) and hyperprolactinemia (p < 0.001) in the aripiprazole group was significantly lower than in the risperidone group. Conclusion: The study demonstrated that aripiprazole, as well as risperidone, had rapid and persistent efficacy for psychotic symptoms from the first week of therapy. There may be poor efficacy for aripiprazole compared with risperidone for overall improvement, but there were no significant differences in this study. Aripiprazole showed good tolerability with less weight gain and hyperprolactinemia compared with risperidone. The overall efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects were similar to that reported in Western populations. (C) 2014 Published by Elsevier B.V.

Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials

A double blinded multicenter clinical trial for evaluating the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia

Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial

Efficacy and Safety of Long-Acting Risperidone on Early Onset Schizophrenia in Adolescent Patients

Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial

Improvement of Social Functioning in Patients with First-Episode Schizophrenia Using Blonanserin Treatment: a Prospective, Multi-Centre, Single-Arm Clinical Trial

Efficacy and Safety of Quetiapine Extended Release Monotherapy in Bipolar Depression: a Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial

Efficacy and Safety of Siponimod for Multiple Sclerosis

Efficacy and Safety of the Domestic Risperidone in Patients with Schizophrenia:a Randomized,Double-blind,Controlled Trial

Safety and effectiveness of oral medium to high dose blonanserin in patients with schizophrenia: subgroup analysis from a prospective, multicenter, post-marketing surveillance study in mainland China

Who Can Benefit More from Its Twelve-Week Treatment: A Prospective Cohort Study of Blonanserin for Patients with Schizophrenia

Efficacy and Safety of Aripiprazole in the Treatment of Schizophrenia: a Randomized, Double-Blind, Risperidone Controlled, Multicenter Study

Double-blind Comparison of Ziprasidone and Risperidone in the Treatment of Chinese Patients with Acute Exacerbation of Schizophrenia

A Randomized,open Label and Parallel-Control Study for the Treatment of Refractory Schizophrenia with Risperidone and Clozapine

Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.

Aripiprazole and risperidone in treatment of the patients with schizophrenia: a randomly clinical trial

Double-blind,double-dummy and randomized controlled study of aripiprazole in the treatment of acute schizophrenia

Risperidone Versus Haloperidol in the Treatment of Acute Exacerbations of Chronic Inpatients with Schizophrenia: a Randomized Double-Blind Study

Randomized, Double-Blind, 6-Week Non-Inferiority Study of Lurasidone and Risperidone for the Treatment of Schizophrenia.

Study on Efficacy and Safety of Risperidone in Treatment of Different Kinds of Schizophrenia

Effects of Alcohol on the Pharmacokinetics of Blonanserin and N-Deethylated Blonanserin in Healthy Chinese Subjects